Clinical Trial Update: BIBF 1120 in Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A Phase 2 study of BIBF 1120 (nintedanib) for recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Ulrik Lassen | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED